Exelon Patch

Quick links to important sections

Exelon Patch

Method of action: Psychoanaleptics

Treatment option: Parkinson Disease, Dementia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Exelon Patch

What is Exelon Patch? (Foundational Overview)

Property Description
Active ingredient Rivastigmine
Form Transdermal patch (Transdermal system)
Pharmacological class Cholinesterase Inhibitor
General purpose Symptomatic treatment to support cognitive functions
Origin Semi-synthetic derivative of physostigmine

Exelon Patch: Identity and Classification

The Exelon Patch is a specific, prescription-only pharmaceutical preparation designed as a transdermal patch that utilizes the active ingredient rivastigmine. Pharmacologically, this medicine belongs to the class of cholinesterase inhibitors, which are established as antidementia medicines used for supportive care. Chemically, rivastigmine is a carbamate derivative and a semi-synthetic derivative that is centrally active, meaning it is capable of crossing the blood-brain barrier to exert its targeted effect. The transdermal patch represents a distinct approach, clinically recognized for offering continuous delivery of the medicine over a 24-hour period.

Transdermal System and General Benefit

The Exelon Patch is engineered as a single-use, adhesive system—specifically a matrix-type transdermal patch—that provides transdermal delivery via the skin, offering a fundamental difference from oral solution and capsule forms. Its core mechanism involves the drug acting as a pseudo-irreversible inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). This dual action is postulated to increase the concentration of the neurotransmitter acetylcholine by slowing the breakdown of this essential chemical messenger. The general purpose of this action is to provide symptomatic treatment by helping to maintain cholinergic function to support cognitive processes such as memory and thinking. This form is typically considered when consistent daily delivery of the active ingredient is a key component of the management strategy.

Regulatory References

  1. EMA European Public Assessment Report (EPAR) for Exelon

What side effects are possible with Exelon Patch?

Exelon Patch: Possible Side Effects and Safety Information

The safety profile of the Exelon Patch is formally documented by regulatory authorities, with adverse reactions organized by frequency and the body systems affected. Side effects are typically related to its function as a cholinesterase inhibitor, primarily involving the gastrointestinal system and local reactions at the application site.

Frequency-Classified Adverse Reactions

Classification Common Adverse Reactions
Very Common (Affect ge 1 in 10 users) Nausea, Vomiting, Diarrhea.
Common (Affect ge 1 in 100 users) Dizziness, Headache, Somnolence (Drowsiness), Anorexia (Decreased Appetite), Weight decrease, Anxiety, Insomnia, Agitation, Delirium, Hallucinations, and Application Site Reactions (e.g., irritation, redness, rash).
Uncommon (Affect ge 1 in 1,000 users) Bradycardia (Slow heart rate), Syncope (Fainting), and Cerebrovascular Accident.

Official Safety Considerations

The most frequent gastrointestinal effects are often dose-related and are reported most commonly when initiating or increasing the dose. Serious adverse reactions documented in regulatory materials include severe dehydration resulting from prolonged vomiting or diarrhea, and medication errors involving the application of multiple patches, which can require hospitalization and have rarely led to death.

Specific population-based safety notes indicate that patients with low body weight (less than 50 kg) may experience more adverse reactions. Furthermore, the patch is contraindicated in patients with severe hepatic impairment and in those with a history of allergic contact dermatitis to the product. Caution is advised for individuals with a history of cardiac conduction delays or gastric ulcers.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with the Exelon Patch is associated with signs of a cholinergic crisis, which results from an overexposure to the active ingredient, rivastigmine. This situation has been documented following medication misuse, such as the accidental application of multiple patches, leading to high exposure.


Documented Manifestations and Complications

Overdose may present with severe gastrointestinal distress (nausea, vomiting, diarrhoea) and systemic signs like bradycardia (slow heart rate), syncope, seizures, and hallucinations. Severe outcomes have been reported, including the risk of life-threatening dehydration and potential cardiac complications such as Torsade de pointes. Patients with low body weight (below 50 kg) or hepatic impairment are officially noted to be at a higher risk for adverse reactions and severe toxicity.


Mandatory Emergency Actions

Immediate medical attention must be sought if an overdose is suspected. Regulatory authorities mandate the immediate removal of all patches to stop the supply of rivastigmine. The treatment for pronounced cholinergic symptoms involves the administration of a specific antidote, atropine. Following the removal of the patches, no further patch should be applied for the next 24 hours. Clinical monitoring, including ECG monitoring, may be required in a hospital setting.

Therapeutic Uses of Exelon Patch

Quick Facts

  • Primary Therapeutic Domain: Management of symptoms associated with dementia.
  • Approved Indications: Mild, moderate, and severe dementia of the Alzheimer's type.
  • Additional Indication: Mild to moderate dementia associated with Parkinson's disease.

Exelon Patch is an established treatment authorized for the symptomatic management of different stages of dementia. It is primarily used to address the memory and cognitive impairments associated with Alzheimer's disease across mild, moderate, and severe classifications.

The medication is also indicated as a therapeutic option for patients experiencing mild to moderate dementia that is associated with Parkinson's disease. The use of this treatment may support efforts to stabilize certain symptoms, which can contribute to the overall quality of life for the patient.

While this treatment may offer support for function and cognition in some individuals, it will not cure or stop the underlying condition from advancing. Decisions regarding its application and continued use should be made with a healthcare professional.

Eligibility and Restrictions for Use

Who can and cannot use Exelon Patch?

Exelon Patch is officially indicated for use in adults diagnosed with mild, moderate, or severe dementia of the Alzheimer's type and mild to moderate dementia associated with Parkinson's disease.


Populations for whom use is contraindicated:

The medicine is contraindicated and must not be used in patients with a known hypersensitivity (allergy) to rivastigmine, to other carbamate derivatives, or to any of the patch's components. Use is also formally prohibited if the patient has a history of an application-site reaction suggestive of allergic contact dermatitis to the rivastigmine patch.


Age and Condition-Based Restrictions

Population Group Eligibility Status (Regulatory)
Pediatric Population Not recommended; no relevant use established for these conditions.
Pregnant/Lactating Women Safety is not established; use is generally advised only if the benefit outweighs the risk.
Severe Organ Impairment Patients with severe liver impairment have not been studied and are contraindicated by some national health authorities.
Low Body Weight Patients weighing less than 50 kg (110 lbs) require special caution and monitoring.

Eligibility is also restricted for patients with certain cardiac conduction defects (like sick sinus syndrome) or active gastrointestinal ulcers, where the medicine should be used with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of the Exelon Patch (rivastigmine) around pharmacodynamic effects and altered drug exposure in specific patient groups.

Category Regulatory Statement on Interaction Pattern
Pharmacodynamic Interactions Co-administration is Not Recommended with cholinomimetics (other cholinesterase inhibitors) due to expected additive cholinergic effects and an increased risk of related adverse reactions.
Systemic anticholinergic medications may have their therapeutic effect reduced due to pharmacodynamic antagonism; co-administration is Not Recommended.
Concomitant use with beta-blockers is Not Recommended due to the risk of additive negative chronotropic effects (slowed heart rate), which may result in bradycardia or syncope.
Other Specific Interactions The use of rivastigmine with metoclopramide is Not Recommended due to an increased risk of extrapyramidal symptoms.
Patients receiving concurrent Nonsteroidal Anti-inflammatory Drugs (NSAIDs) should be monitored for symptoms of active or occult gastrointestinal bleeding.
As a cholinesterase inhibitor, rivastigmine is expected to exaggerate the effects of succinylcholine-type muscle relaxants used during anesthesia.
Metabolic/PK Profile No clinically significant pharmacokinetic interactions are expected with medicines that inhibit or induce Cytochrome P450 (CYP) enzymes, as rivastigmine is primarily metabolized by esterases.
Population Exposure Notes Hepatic impairment (mild to moderate) and renal impairment (moderate to severe) are associated with reduced clearance and increased systemic exposure of the drug.

No drug-drug combinations are formally classified as Contraindicated. The regulatory labels do not document clinically significant interactions with food, alcohol, or herbal products for the transdermal system.

Mechanism of Action

The action of the Exelon Patch is defined by its core ingredient, rivastigmine, which operates across two main mechanistic domains to influence central nervous system function.

Dual Inhibition of Cholinesterase Enzymes

The patch acts within the domain of enzyme-mediated signaling by functioning as a pseudo-irreversible inhibitor of both Acetylcholinesterase (AChE) and Butyrylcholinesterase (BuChE). This mechanism directly prevents the rapid breakdown of the neurotransmitter acetylcholine (ACh), a fundamental step that increases the duration and concentration of ACh at the synapse.

Enhancement of Cholinergic Neurotransmission

This effect modulates the key cholinergic pathway in the central nervous system, particularly in areas like the cortex and hippocampus, where ACh is essential for attention and memory signaling. By increasing the concentration of ACh, the drug leads to altered signaling dynamics within neural circuits, which affects the physiological processes of these brain areas.

Alteration of Systemic Cholinergic Activity

Beyond the brain, the mechanism influences cholinergic activity throughout the body, engaging both the central and peripheral nervous systems. This results in predictable physiological adjustments, such as alterations in gastrointestinal motility and heart rate, which are direct physiological consequences of the enzyme inhibition.

Dosage and Administration Information

How to Use Exelon Patch: Official Administration Guidelines

The Exelon Patch is a transdermal delivery system designed for daily application to the skin. Strict adherence to the official administration schedule is required to ensure consistent delivery of the medicine over a 24-hour period.

Application Procedure

  1. Remove the Used Patch: Take off the patch from the previous day before applying a new one. Do not wear more than one patch at a time.
  2. Inspect and Prepare: Open the new pouch only when ready to use. The patch must not be cut, folded, or altered in any way. The application site must be clean, dry, intact skin that is free of creams, powders, or oil.
  3. Apply: Peel off the protective liner. Apply the sticky side to a new, approved area of skin, pressing it firmly for at least 30 seconds to ensure the edges stick well. Approved sites are the upper or lower back, upper arm, or chest.
  4. Site Rotation: The patch must be applied to a different skin site every day. Do not use the exact same skin area again for at least 14 days.
  5. Replacement: Apply a new patch after 24 hours, replacing it at the same time of day.

Dosing and Missed Doses

Treatment begins with the 4.6 mg/24 hours patch once daily. Doses are typically increased, or titrated, only after a minimum of four weeks at the previous dose and only if the lower dose was well-tolerated. The maximum daily dose is 13.3 mg/24 hours.

If a patch is forgotten or falls off, apply a new patch immediately and return to the normal application time the following day. If treatment is interrupted for more than three consecutive days, the patient must restart treatment using the initial 4.6 mg/24 hours dose and follow the standard titration schedule.

Recent Clinical Evidence

Exelon Patch: Recent Clinical Evidence

Research studies have evaluated the use of the rivastigmine transdermal patch (Exelon Patch) for the symptomatic treatment of dementia associated with Alzheimer's disease (AD) and Parkinson's disease. The transdermal route was developed to provide continuous delivery of the drug, which may offer improved tolerability when compared to the oral capsule formulation.

Key Clinical Trial Findings

Major randomized controlled trials, such as the IDEAL study, explored the effectiveness of the patch in patients with mild to moderate AD. Findings indicated that the 9.5 mg/24 hours patch formulation provided a similar effect on measures of cognitive function and daily activities compared to the highest recommended oral dose (12 mg/day) of rivastigmine capsules.

Studies also examined higher dosages, with the 13.3 mg/24 hours patch dose being evaluated in patients with severe AD. The ACTION study, a randomized, controlled trial, reported that the 13.3 mg/24 hours patch was associated with statistically different outcomes on measures of cognition (Severe Impairment Battery) and daily functioning compared to the 4.6 mg/24 hours patch, without a significant increase in overall adverse events.

Safety and Tolerability Profile

The transdermal patch delivery system is associated with a lower incidence of common gastrointestinal adverse events (such as nausea and vomiting) compared to the oral capsules. However, use of the patch introduces the risk of application site reactions, which include redness or irritation. These skin reactions are typically mild to moderate in severity and can often be managed through simple measures like regular rotation of the patch application site.

Key Studies & References

  1. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type (Review mentioning gastrointestinal tolerability and skin reactions)

Frequently Asked Questions (FAQ)

Common questions about Exelon Patch (FAQ)

Q: Does the Exelon Patch treat all types of memory loss?

According to official regulatory information, this medicine is indicated only for the treatment of dementia that is specifically associated with Alzheimer's disease and mild to moderate dementia associated with Parkinson's disease. Its use is limited to these specific conditions as outlined in the official product documents.


Q: Is Exelon Patch used for anything other than Alzheimer's or Parkinson's dementia?

The official indication for the Exelon Patch is the treatment of dementia of the Alzheimer's type and mild to moderate dementia associated with Parkinson's disease. Regulatory documents focus on these specific diagnoses for its approved use.


Q: If I miss a day of using the patch, what should I do?

Official administration guidelines state that if treatment is interrupted for three days or fewer, it can be restarted using the same or a lower strength patch. However, if the interruption lasts for more than three consecutive days, regulatory guidance recommends restarting treatment at the initial dose strength in that case.


Q: Does using Exelon Patch mean the condition will not get worse?

Studies and regulatory rationale indicate that this medicine provides symptomatic treatment to help support cognitive functions. There is no evidence in the regulatory rationale that it alters the underlying course of the dementing disease process.


Q: Is the Exelon Patch considered a cure for memory problems?

The Exelon Patch is officially classified as a symptomatic treatment. Its purpose is to support cognitive processes such as memory and thinking, but it is not considered a cure for memory problems.


Q: What criteria do doctors use to decide who should start using the Exelon Patch?

Eligibility for use is officially based on having a confirmed diagnosis of dementia associated with Alzheimer's or Parkinson's disease. This diagnosis is often supported by a validated cognitive assessment, as defined in official coverage criteria.


Q: Is the transdermal delivery method considered more reliable than pills?

The patch delivery system was developed to provide continuous delivery of the drug. Clinical trial data indicates the transdermal system is associated with a lower rate of common gastrointestinal adverse reactions, such as nausea and vomiting, when compared to the oral capsule form.


Q: Are there any common reasons why the Exelon Patch would not stick properly?

Official administration instructions specify that the patch should be applied to clean, dry, hairless, intact skin. Regulatory guidance also advises that the skin be free of creams, powders, or oils, as these factors may potentially affect proper adherence.


Q: Can I shower, swim, or bathe while wearing the Exelon Patch?

Official instructions confirm that the patch may be worn during bathing and in hot weather. However, users are reminded that the patch must stay adhered to the skin for the full 24-hour period.


Q: Does sun exposure or heat affect how the Exelon Patch works?

Official warnings advise users to avoid prolonged exposure to external heat sources. These sources include excessive sunlight, sunlamps, saunas, hot tubs, or heating pads, as heat may potentially increase the amount of medicine absorbed.


Q: What happens if a child or pet touches or chews a used Exelon Patch?

Official warnings emphasize that all patches, both new and used, must be kept out of the reach and sight of children and pets. This is due to the importance of preventing accidental exposure to the residual medicine, as contact can pose a safety risk.


Q: What are the most commonly reported side effects when first starting the Exelon Patch?

Gastrointestinal adverse reactions, such as nausea, vomiting, diarrhea, and decreased appetite, are reported most frequently when treatment is first initiated or when the dose is increased. These effects are documented as very common adverse reactions.


Q: Is weight loss a potential concern for users of the Exelon Patch?

Weight decrease and decreased appetite are listed as common adverse reactions in the official safety information. Regulatory warnings indicate that patients weighing less than 50 kg require special caution and monitoring.


Q: Can the Exelon Patch cause stomach issues like nausea or vomiting?

Nausea and vomiting are listed as very common adverse reactions in the official safety profile. Prolonged vomiting or diarrhea is a serious concern due to the potential for severe dehydration.


Q: Why is it important to change the patch application site daily?

The application site must be rotated daily to a new area of the skin to help prevent irritation. Regulatory instructions specify that a different skin site must be used for each patch to minimize the risk of application site reactions.


Q: Are there any foods or drinks that should be avoided while using Exelon Patch?

The regulatory label for the transdermal system does not typically document clinically significant interactions with food, alcohol, or common herbal products. Any specific concerns regarding interactions may be reviewed with a healthcare professional.


Q: Can Exelon Patch affect sleep patterns?

Insomnia, which is difficulty sleeping, is listed as a common adverse reaction in the official product information. This indicates that the medicine may affect a user's sleep patterns.


Q: Can people with heart conditions use the Exelon Patch?

Official warnings state that caution is advised for individuals with a history of certain cardiac conditions, such as cardiac conduction delays like sick sinus syndrome. These warnings are in place due to the drug's effect on heart rate and circulation.


Q: What does the FDA Black Box Warning mean for Exelon Patch users?

The official safety warnings describe serious adverse reactions, including hospitalization and, rarely, death, that have resulted from medication errors. These errors specifically involve wearing more than one patch at a time, which is a major safety concern highlighted in regulatory documents.


Q: Is it safe to get an MRI while wearing the Exelon Patch?

Official patient precaution information recommends that the patch be removed before undergoing a Magnetic Resonance Imaging (MRI) procedure.


Q: Can the Exelon Patch make a person feel dizzy or lightheaded?

Dizziness is listed as a common adverse reaction in the official product information. Syncope, which is fainting, is also listed as an uncommon adverse reaction associated with the use of this medicine.


Q: Can pregnant or breastfeeding women use the Exelon Patch?

Official safety data indicates that the safety of the medicine is not established for use during pregnancy or breastfeeding. Use is generally advised only if the potential benefit justifies the potential risk. This decision is based on an assessment of individual benefit versus risk.


Q: Does the Exelon Patch interact with herbal supplements like St. John's Wort?

The regulatory label for the transdermal system does not document clinically significant pharmacokinetic interactions with common herbal products. Disclosure of all supplements used to a healthcare professional is standard practice.


Q: What common over-the-counter pain relievers can be used with Exelon Patch?

The official product information states that patients receiving Nonsteroidal Anti-inflammatory Drugs (NSAIDs) should be monitored for symptoms of gastrointestinal bleeding. Monitoring for this potential effect is required.


Q: If the patch comes into contact with another person, is that a safety concern?

Official warnings on the risk of accidental overdose emphasize the importance of proper handling and safe disposal. These instructions are in place to prevent accidental exposure to others, as contact with the residual medicine can pose a safety risk.


Q: If a person has a fever, does it affect the absorption of the Exelon Patch?

Warnings state that external heat can increase the amount of medicine absorbed by the skin. Based on this, conditions that significantly increase internal body temperature, such as a fever, may also potentially affect the absorption of the patch.


Q: Does the use of nicotine patches or gum affect the Exelon Patch?

The official product documents advise that co-administration with other medicines that affect the same body system is not recommended. This is due to the expected risk of additive effects.

How should Exelon Patch be stored and disposed of?

Storage and Disposal of Exelon Patch

The Exelon Patch (rivastigmine transdermal system) must be stored and handled according to official regulatory specifications.

Storage Requirements

Requirement Description
Temperature Store at controlled room temperature, typically 20°C to 25°C. Do not refrigerate or freeze.
Protection Keep the patch away from direct light, moisture, and excessive external heat sources, such as heating pads or saunas.
Packaging Store in the individually sealed pouch until ready for immediate application. Do not use if the pouch seal is broken.
Child Safety Keep all patches, new and used, out of the reach and sight of children and pets.

Disposal Instructions

Used patches must be handled carefully due to residual medication. Immediately after removal, the patch must be folded in half with the adhesive sides together. Place the folded patch back into the original pouch and discard it safely in the trash. Unused or expired patches should be disposed of according to local regulatory requirements; they must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Exelon Patch found in:

A-Z Index: